BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23762093)

  • 21. Anabolic agents: a new chapter in the management of osteoporosis.
    Khan AW; Khan A
    J Obstet Gynaecol Can; 2006 Feb; 28(2):136-41. PubMed ID: 16643716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteoporosis prevention and treatment: its relevance to breast cancer patients.
    Hodsman AB
    Can J Oncol; 1995 Dec; 5 Suppl 1():28-32. PubMed ID: 8853521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letter to the Editor: Strontium Ranelate in the Treatment of Osteoporosis: A Possible Mechanism.
    Sugiyama T; Kim YT; Oda H
    J Clin Endocrinol Metab; 2016 May; 101(5):L64-5. PubMed ID: 27163476
    [No Abstract]   [Full Text] [Related]  

  • 24. Restoring aging bones.
    Rosen CJ
    Sci Am; 2003 Mar; 288(3):70-7. PubMed ID: 12616861
    [No Abstract]   [Full Text] [Related]  

  • 25. [Bone remodeling].
    Lerner UH; Ljunggren O
    Lakartidningen; 2006 Oct 4-10; 103(40):2972-5. PubMed ID: 17115661
    [No Abstract]   [Full Text] [Related]  

  • 26. A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women.
    Lambert MNT; Hu LM; Jeppesen PB
    Am J Clin Nutr; 2017 Sep; 106(3):801-811. PubMed ID: 28768649
    [No Abstract]   [Full Text] [Related]  

  • 27. The immune system and bone.
    Pacifici R
    Arch Biochem Biophys; 2010 Nov; 503(1):41-53. PubMed ID: 20599675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
    Takata S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
    [No Abstract]   [Full Text] [Related]  

  • 29. [Diagnosis and treatment of postmenopausal osteoporosis].
    Mizunuma H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():490-4. PubMed ID: 18161154
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
    Rhee Y; Song K; Park S; Park HS; Lim SK; Park BW
    Endocr J; 2013; 60(2):167-72. PubMed ID: 23064476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab for postmenopausal osteoporosis?
    Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective.
    Zhao R
    Int J Med Sci; 2012; 9(9):825-32. PubMed ID: 23136547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FSH and TSH in the regulation of bone mass: the pituitary/immune/bone axis.
    Colaianni G; Cuscito C; Colucci S
    Clin Dev Immunol; 2013; 2013():382698. PubMed ID: 23818914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmenopausal osteoporosis and hormone replacement therapy.
    Gambacciani M; Vacca F
    Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bone histology in postmenopausal osteoporosis--variations in cellular activity].
    Lozo P; Krpan D; Krvavica A; Vukelić Baturić T; Fistonić I; Kusec V
    Acta Med Croatica; 2004; 58(1):5-11. PubMed ID: 15125387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of curcumin on the skeletal system in rats.
    Folwarczna J; Zych M; Trzeciak HI
    Pharmacol Rep; 2010; 62(5):900-9. PubMed ID: 21098873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for treatment to prevent fragility fractures in postmenopausal women.
    Geusens P
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
    Chavassieux P; Chapurlat R; Portero-Muzy N; Roux JP; Garcia P; Brown JP; Libanati C; Boyce RW; Wang A; Grauer A
    J Bone Miner Res; 2019 Sep; 34(9):1597-1608. PubMed ID: 31233639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cellular and clinical parameters of anabolic therapy for osteoporosis.
    Rosen CJ
    Crit Rev Eukaryot Gene Expr; 2003; 13(1):25-38. PubMed ID: 12839095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen regulation of immune cell bone interactions.
    Weitzmann MN; Pacifici R
    Ann N Y Acad Sci; 2006 Apr; 1068():256-74. PubMed ID: 16831927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.